Status:
COMPLETED
The Safety and Efficacy of Fecal Microbiota Transplant (FMT) for Steroid-refractory Graft-versus-host Disease
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
GVHD
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This clinical study evaluates the safety and efficacy of fecal microbiota transplantation (FMT) in patients with steroid-refractory graft-versus-host disease (GVHD).
Eligibility Criteria
Inclusion
- Able and willing to sign the informed consent form and complete follow-up;
- Aged 18-65 years, regardless of gender;
- Patients with refractory GVHD.
Exclusion
- life-threatening or associated with severe non-GvHD complications;
- Persistent malignant conditions;
- Patients who have undergone second or multiple hematopoietic stem cell transplants;
- History of severe allergic reactions;
- Any condition that the investigator considers unsuitable for inclusion (such as any history, treatment history, or abnormal test data that may confound the study results, interfere with full participation in the study, or harm the patient's interests);
Key Trial Info
Start Date :
April 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2024
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT06938165
Start Date
April 27 2020
End Date
June 30 2024
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang hospital
Guangzhou, Guangdong, China, 520000